An international clinical trial led by investigators from Brigham and Women’s Hospital a founding member of the Mass General Brigham healthcare system found that finerenone reduced the composite of total first and recurrent heart failure events defined as hospitalizations for heart failure or urgent heart failure visits and cardiovascular death among patients with heart failure and mildly reduced or preserved ejection fraction. The rates of heart failure events and cardiovascular death were lower in the finerenone group compared with the placebo group. The overall rate of serious adverse events was similar across groups, but more persons taking finerenone developed hyperkalemia or had higher potassium levels.
Their findings were published in the New England Journal for Medicine.
We saw benefit regardless of the ejection fraction and even in patients who were on other approved therapies,
This drug represents a new drug class that may become a pillar of therapy for this disease.
Scott Solomon, MD
Heart failure is the progressive inability of the heart to fill with and pump blood. It is estimated that more than 60 million people are affected by HF worldwide. It was estimated that nearly half of all patients living with HF have mildly reduced or preserved left ventricular ejection fraction-a condition where treatment options are still very limited. These findings suggest that the non-steroidal mineralocorticoid receptor antagonist finerenone might be a novel therapeutic option for patients.
Also, Read| Research finds Alzheimer’s like changes in COVID-19 patients
The Bayer-funded, randomized FINEARTS-HF trial had recruited 6,000 patients to either finerenone or placebo, on the background of existing therapies. Again the numbers of Black patients were low, but the proportions were satisfactory for those countries.
Our group continues to study novel therapies for heart failure,
There’s huge residual risk in these patients and so more room for new therapies.
Scott Solomon, MD
Source: Brigham and Women’s Hospital – Press Release
Journal Reference: Solomon, Scott D et al. “Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.” The New England journal of medicine, 10.1056/NEJMoa2407107. 1 Sep. 2024, DOI: 10.1056/NEJMoa2407107
Last Modified:
